Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 8/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802821 | 0.89 | TP53 (0.44) | F10TP53RAF1BRAFMAPT | |
| SCHEMBL6808414 | 0.88 | F10 (0.61) | F10TP53RAF1BRAFMAPT | |
| SCHEMBL6812265 | 0.82 | TP53 (0.47) | F10TP53RAF1BRAFMAPT | |
| SCHEMBL6813074 | 0.80 | TP53 (0.45) | F10TP53RAF1BRAFMAPT | |
| SCHEMBL6808014 | 0.80 | F10 (0.71) | F10PTGS2MAPTPOLBKDM4E | |
| SCHEMBL7140391 | 0.76 | PTGS2 (0.43) | F10PTGS2RAF1BRAFMAPK14 | |
| SCHEMBL5164490 | 0.76 | L3MBTL1 (0.52) | TP53MAPTPOLB | |
| SCHEMBL6806790 | 0.73 | TP53 (0.46) | F10TP53MAPTPOLBKDM4E | |
| SCHEMBL6807934 | 0.69 | MAPT (0.46) | TP53RAF1BRAFMAPTPOLB | |
| SCHEMBL5445168 | 0.69 | F10 (0.63) | F10PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | claimed |
| EP-1370522-A1 | PHENYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOEMBOLIC DISORDERS OR TUMOURS | MERCK PATENT GmbH (DE) | 2003-12-17 | — | — | EP | claimed |
| WO-2002070471-A1 | PHENYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOEMBOLIC DISORDERS OR TUMOURS | MERCK PATENT GMBH (DE) | 2002-09-12 | — | — | WO | claimed |
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | RCOR3, F2, NCOR2 | F10 64/4885PTGS2 380/4885TP53 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.